CMPX - NASDAQ

Compass Therapeutics, Inc.

CMPX·NASDAQ

$2.13

+2.4%

HealthcareBiotechnology

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$294.55M

EPS-0.4200

P/E Ratio-5.07

Earnings Date08/10/2026

cmpx

Other Non-Current Assets

Last Annual Value

568.00K

3-Year CAGR

21%

5-Year CAGR

-1%

10-Year CAGR

17%

Adjust for Inflation

Compass Therapeutics, Inc. Competitors Analysis of Other Non-Current Assets

CMPX · NASDAQ

Company	Other Non-Current Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Compass Therapeutics, Inc. NASDAQ:CMPX	568.00K	21.1%	12.2%	N/A
Ocugen, Inc. NASDAQ:OCGN	4.78M	3.7%	19.6%	42.7%
Omeros Corporation NASDAQ:OMER	97.49M	-11.3%	-7.2%	N/A
Monopar Therapeutics Inc. NASDAQ:MNPR	0.00	N/A	N/A	N/A
4D Molecular Therapeutics, Inc. NASDAQ:FDMT	120.57M	460.7%	188.6%	N/A
Fulcrum Therapeutics, Inc. NASDAQ:FULC	1.74M	-17.6%	26.3%	N/A
Gossamer Bio, Inc. NASDAQ:GOSS	408.00K	-12.9%	-17.7%	N/A
Corvus Pharmaceuticals, Inc. NASDAQ:CRVS	855.00K	112.6%	29.4%	-8.2%
Lexicon Pharmaceuticals, Inc. NASDAQ:LXRX	29.37M	228.6%	N/A	51.5%
KalVista Pharmaceuticals, Inc. NASDAQ:KALV	2.37M	181.7%	63.9%	N/A

Compass Therapeutics, Inc. Fair Value Envelope

CMPX · NASDAQ

Our analysis suggests that CMPX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.13, this represents a potential HIDDEN relative to our calculated worth for Compass Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $2.13

Related Guides

Blog Categories

Continue your CMPX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.